| Literature DB >> 36014063 |
Pedro Vieira-Baptista1,2, Joana Lima-Silva1,2, Mario Preti3, Carlos Sousa4, Fernanda Caiano1, Colleen K Stockdale5, Jacob Bornstein6.
Abstract
Leptothrix are long bacteria of rare occurrence; although these bacteria have been implicated in causing vaginal symptoms identical to candidiasis, studies on prevalence and effect on overall vaginal health are lacking. In this study, we evaluated data of women referred to a private clinic for treating vulvovaginal symptoms (n = 1847) and reassessed data of our previous and ongoing studies (n = 1773). The overall rate of leptothrix was 2.8% (102/3620), and the mean age of affected women was 38.8 ± 10.65 years (range 18-76). The majority of the women with leptothrix had normal vaginal flora (63.7% [65/102]). Leptothrix was associated with a higher risk of candidiasis (relative risk (RR) 1.90, 95% confidence interval (CI) 1.1600-3.1013; p = 0.010) and a lower risk of bacterial vaginosis (RR 0.55, 95% CI, 0.3221-0.9398; p = 0.029) and cytolytic vaginosis (RR 0.11, 95% CI, 0.0294-0.4643; p = 0.002). No cases of trichomoniasis were observed. Human immunodeficiency virus infection increased the risk of leptothrix (RR 3.0, 95% CI, 1.6335-5.7245; p = 0.000). Among the women evaluated for vulvovaginal symptoms, 2.4% (45/1847) had leptothrix, and in 26.7% (12/45), leptothrix was considered the causative entity. This study suggests that leptothrix occurrence is rare; it remains unresolved if it can be a cause of vulvar symptoms.Entities:
Keywords: candidiasis; dysbiosis; lactobacillosis; leptothrix; vaginal flora; wet mount microscopy
Year: 2022 PMID: 36014063 PMCID: PMC9415594 DOI: 10.3390/microorganisms10081645
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Leptothrix and normal background flora (×400).
Characteristics of women referred for an appointment due to vulvovaginitis and in which leptothrix was found. Women were divided into 2 groups according to whether leptothrix was considered as the final sole diagnosis or if another diagnosis could explain the symptoms.
| Leptothrix | Other Diagnosis | ||
|---|---|---|---|
| Age (mean ± SD) (years) | 35.5 ± 9.27 | 37.4 ± 11.27 | 0.604 |
| Smoking | 8.3% (1/12) | 6.1% (2/33) | 0.787 |
| Menopause | 0% (0/12) | 6.1% (2/33) | 0.383 |
| Duration of symptoms (mean ± SD) and range (months) | 12.8 ± 9.36 | 54.5 ± 67.57 | 0.040 |
| Contraception | |||
| - None | 25.0% (3/12) | 38.7% (12/31) | 0.397 |
| - Condom | 0% (0/12) | 3.2% (1/31) | 0.529 |
| - Combined oral contraceptives | 50.0% (6/12) | 41.9% (13/31) | 0.633 |
| - Progestin only pill | 16.7% (2/12) | 3.2% (1/31) | 0.121 |
| - Intrauterine devices | 8.3% (1/12) | 9.7% (3/31) | 0.890 |
| - Vaginal ring | 0% (0/12) | 3.2% (1/31) | 0.529 |
| Symptoms | |||
| - Burning | 91.7% (11/12) | 63.6% (21/33) | 0.067 |
| - Itching | 33.3% (4/12) | 45.4% (15/33) | 0.467 |
| - Dryness | 0% (0/12) | 12.1% (4/33) | 0.206 |
| - Pain (spontaneous) | 16.7% (2/12) | 15.2% (5/33) | 0.902 |
| - Dyspareunia | 70% (7/10) | 67.8% (19/28) | 0.899 |
| - Dysuria | 8.3% (1/12) | 12.1% (4/33) | 0.720 |
| - Discharge | 66.7% (8/12) | 33.3% (11/33) | 0.045 |
| - Cyclical symptoms | 58.3% (7/12) | 41.9% (13/31) | 0.334 |
| Previous treatments | |||
| - Antifungals | 75.0% (9/12) | 60.1% (20/33) | 0.372 |
| - Antibiotics | 100% (12/12) | 24.2% 8/33 | 0.000 |
| - Probiotics | 25.0% (3/12) | 3.0% (1/33) | 0.022 |
| Final diagnosis | |||
| - Aerobic vaginitis/desquamative inflammatory vaginitis | 1 | ||
| - Bacterial vaginosis | 1 | ||
| - Candidiasis | 12 | ||
| - Cytolytic vaginosis | 1 | ||
| - | 1 | ||
| - Lichen sclerosus | 7 | ||
| - Pelvic floor dysfunction | 1 | ||
| - Vulvodynia | 8 | ||
| - Vulvar involvement of Crohn’s disease | 1 |
SD: standard deviation.
Age, reason for referral and additional symptoms, treatments prescribed, and outcome of women in group A with a final diagnosis of leptothrix. 1—metronidazole 500 mg vaginal ovules id for 10 days and then 2–3 times a week for 3 months; 2—amoxicillin 875 mg + clavulanate 125 mg pills, twice a day for 10 days; 3—sodium bicarbonate 30–40 g/L used in vaginal irrigations twice a day for 2 weeks and then as needed for symptom control; 4—dequalinium chloride 10 mg vaginal pills once a day for 12 days and then 2–3 times a week for 3 months.
| Case | Age | Reason of Referral | Other Symptoms | Treatment | Outcome | Notes |
|---|---|---|---|---|---|---|
| 1 | 44 | Burning and itching | Dyspareunia and discharge | Metronidazole 1 | Lost to follow-up | |
| 2 | 25 | Dyspareunia | Burning and discharge | Metronidazole 1 | Lost to follow-up | |
| 3 | 29 | Burning and itching | Discharge | Metronidazole 1 | Partial improvement | No further improvement with sodium bicarbonate |
| 4 | 51 | Burning | Dyspareunia and discharge | Metronidazole 1 | Lost to follow-up | |
| 5 | 29 | Burning | Dyspareunia and discharge | Amoxicillin + clavulanate 2 | No improvement | Asymptomatic with metronidazole |
| 6 | 45 | Discharge | None | None | Not applicable | |
| 7 | 41 | Burning | Burning | Sodium bicarbonate 3 | Asymptomatic | |
| 8 | 24 | Burning | Dyspareunia | Dequalinium chloride 4 | Asymptomatic | |
| 9 | 32 | Burning | Discharge | Sodium bicarbonate 3 | Partial improvement | No further improvement with sodium bicarbonate or amoxicillin + clavulanate |
| 10 | 31 | Burning | Discharge | Metronidazole 1 | Asymptomatic | |
| 11 | 46 | Burning and itching | Dyspareunia | Sodium bicarbonate 3 | Lost to follow-up | |
| 12 | 29 | Burning and itching | Dyspareunia and discharge | Metronidazole 1 | Partial improvement |
Evaluation of previous and ongoing studies by the authors in which wet mount microscopy was performed and data about leptothrix is available on file. The total number of cases may differ from the figures shown in the published studies, as we evaluated all cases available, regardless of inclusion in the final analysis. Inflammation was defined as >10 leukocytes per high power field.
| Group | Study | Year of the Study | Objectives | Population | N | Rate of Leptothrix | Associated Conditions | Comments |
|---|---|---|---|---|---|---|---|---|
| A | Evaluation of women with vulvovaginal symptoms | 2022 | To evaluate the prevalence and characteristics of women with leptothrix | Women attending a private practice with vulvovovaginal symptoms | 1847 | 2.4% (45/1847) | BV = 13.3% (6/45) | The diagnosis of leptothrix was considered in 26.7% (12/45) of cases with leptothrix |
| B | Ongoing (study evaluating methylation markers and vaginal flora in HPV positive women) | 2022 | To evaluate the correlation between cervical dysplasia, HPV, cervical dysplasia, methylation markers and vaginal flora | Women referred for colposcopy from the organized screening program | 392 | 2.3% (9/392) | BV= 22.2% (2/9) | One case of CIN3/AIS |
| Wet Mount Microscopy of the Vaginal Milieu Does Not Predict the Outcome of Fertility Treatments: A Cross-sectional Study [ | 2022 | To evaluate if women with dysbiosis subjected to fertility treatments have lower rates of pregnancy. | Women who underwent fertility treatments at a fertility clinic | 500 | 3.2% (16/500) | BV = 6.2% (1/16) | There were no differences according to the presence or absence of leptothrix in biochemical pregnancy (28.6% vs. 27.5%, | |
| Clinical validation of a new molecular test (Seegene Allplex™ Vaginitis) for the diagnosis of vaginitis: a cross-sectional study [ | 2021 | To validate a molecular assay in the diagnosis of candidiasis, | Consecutive symptomatic and asymptomatic women | 758 | 2.9% (22/758) | BV = 13.6% (3/22) | ||
| Wet mount characterization of the vaginal flora of HIV women [ | 2017 | To evaluate the vaginal flora in women living with HIV | Women living with HIV | 123 | 8.1% (10/123) | BV = 20% (2/10) | All women with leptothrix were using antiretroviral treatment | |
| Total | - | - | - | 3620 | 2.8% (102/3620) | BV = 13.7% (14/102) |
* Agreement between culture, PCR and WMM; § only cases in which PCR was performed. AIS: adenocarcinoma in situ; BV: bacterial vaginosis; AV/DIV: aerobic vaginitis/desquamative inflammatory vaginitis; CIN: cervical intraepithelial neoplasia; CV: cytolytic vaginosis; NA: not available.
Figure 2Age distribution of women with leptothrix.
Figure 3Vaginal pH distribution in women with leptothrix.